You are here: Industry Insights > Rhythm

News List

Rhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl Syndrome firstwordpharma
July 29, 2021
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced a collaborative research agreement with the CRIBBS.
Rhythm Receives Rare Pediatric Disease Designation for POMC, LEPR Deficiency Obesity Treatment americanpharmaceuticalreview
July 13, 2020
Rhythm Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designations for setmelanotide.
AI-Enabled ECG During Normal Sinus Rhythm Identifies A-Fib drugs
August 05, 2019
An artificial intelligence (AI)-enabled electrocardiograph (ECG) acquired during normal sinus rhythm can identify individuals with atrial fibrillation...
Flagship cancer startup Torque gets $25M, Rhythm founder as CEO fiercebiotech
November 15, 2017
Flagship Pioneering has launched its latest biotech, Torque, as it hopes to power through using a new class of “deep-primed” immune cell therapies in cancer.
Rhythm Expands Phase 2 Clinical Trials of Setmelanotide for the Treatment of Bardet-Biedl Syndrome O americanpharmaceuticalreview
May 18, 2017
Rhythm announced the expansion of the company's Phase 2 clinical trials of setmelanotide to the treatment of Bardet-Biedl syndrome (BBS) obesity.
Rhythm Starts Phase 3 Clinical Trial of Setmelanotide americanpharmaceuticalreview
May 05, 2017
Rhythm announced the initiation of a Phase 3 clinical trial to evaluate the safety and efficacy of setmelanotide, the company's melanocortin-4 receptor (MC4R) agonist...